Video

Dr. Chen on FLASH Trial Results in CTCL

Pei-Ling Chen, MD, PhD, gives her perspective on results from the phase 3 FLASH trial investigating synthetic hypericin in CTCL.

Pei-Ling Chen, MD, PhD, is a member of the Pathology and Cutaneous Oncology Departments at Moffitt Cancer Center and a member of the Moffitt Cutaneous Lymphoma Multidisciplinary Clinic specializing in the research and treatment of patients with cutaneous T-cell lymphoma (CTCL).

Chen offers her thoughts on results from the phase 3 FLASH trial (NCT02448381) analyzing synthetic hypericin (HyBryte) for patients with CTCL. Hypericin is a potent photosensitizer applied to skin lesions that is taken up by the malignant T cells, and then activated by visible light 16 to 24 hours later.

In data published in June 2022, investigators found that hypericin induced a response rate of 16% vs 4% with placebo (P = .04) following 6 weeks of therapy. Chen said hypericin may represent an important new therapy for patients with early-stage disease.

Related Videos
Benjamin Besse, MD, PhD, director, clinical research, Gustave Roussy Institute; professor, medical oncology, Paris-Saclay University
Fred Saad, CQ, MD, FRCS, FCAHS
Eric Kumar Singhi, MD
Seth Wander, MD, PhD
Lillian L. Siu, MD, FRCPC
Marc Machaalani, MD
Mark Awad, MD, PhD, chief, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
Rasha Cosman, BSc, MBBS, FRACP
Saad Z. Usmani, MD, MBA, FACP, FASCO
Nicholas P. McAndrew, MD, MSCE